Type (Eponym) Enzyme deficiency (Gene) Incidence (births) Hypo-glycemia? Hepato-megaly? Hyperlip-idemia? Muscle symptoms Development/ prognosis Other symptoms<unk>  0<unk>  synthase (GYS2) ? Yes No No Occasional muscle cramping Growth failure in some cases<unk>  I /<unk>  1 (von Gierke's<unk>  Glucose-6-phosphatase (G6PC / SLC37A4) 1 in 50,000 – 100,000 Yes Yes Yes None Growth failure Lactic acidosis, hyperuricemia<unk>  II /<unk>  2 (Pompe<unk>  ) Acid alpha-glucosidase (GAA) 1 in 13,000. No Yes No Muscle weakness Progressive proximal skeletal muscle weakness with varied timeline to threshold of functional limitation (early childhood to adulthood). Approximately 15% of the Pompe population is classified as infantile Pompe which is typically deadly within the first year if untreated. Heart failure (infantile), respiratory difficulty (due to muscle weakness)<unk>  III /<unk>  3 (Cori's<unk>  or Forbes'<unk> <unk>  debranching enzyme ( AGL) 1 in 100,000 Yes Yes Yes Myopathy<unk>  IV /<unk>  4 (Andersen<unk> <unk>  branching enzyme (GBE1) 1 in 500,000 No Yes, also cirrhosis No Myopathy and dilated cardiomyopathy Failure to thrive, death at age ~5 years<unk>  V /<unk>  5 (McArdle<unk>  Muscle<unk>  phosphorylase (PYGM) 1 in 100,000 – 500,000 No No No Exercise-induced cramps, Rhabdomyolysis Renal failure by myoglobinuria, second wind phenomenon<unk>  VI /<unk>  6 (Hers'<unk>  Liver<unk>  phosphorylase (PYGL) Muscle phosphoglycerate mutase (PGAM2) 1 in 65,000 – 85,000 Yes Yes Yes None initially benign, developmental delay follows.<unk>  VII /<unk>  7 (Tarui's<unk>  Muscle phosphofructokinase (PFKM) 1 in 1,000,000 No No No Exercise-induced muscle cramps and weakness developmental delay In some haemolytic anaemia<unk>  IX /<unk>  9 Phosphorylase kinase (PHKA2 / PHKB / PHKG2 / PHKA1) ? Yes Yes Yes None Delayed motor development, Developmental delay<unk>  X /<unk>  10 Phosphoglycerate mutase ( PGAM2) ? ? ? ? Exercise-induced muscle cramps and weakness Myoglobinuria<unk>  XI /<unk>  11 Muscle lactate dehydrogenase (LDHA) ? ? ? ? Fanconi-Bickel syndrome formerly<unk>  XI /<unk>  11, no longer considered a<unk>  Glucose transporter (GLUT2) ? Yes Yes No None<unk>  XII /<unk>  12 Aldolase A (ALDOA) ? No In some No Exercise intolerance, cramps. In some Rhabdomyolysis. Hemolytic anemia and other symptoms<unk>  XIII /<unk>  13 β-enolase (ENO3) ? No ? No Exercise intolerance, cramps Increasing intensity of myalgias over decades Serum CK: Episodic elevations; Reduced with rest<unk>  XV /<unk>  15<unk> in-1 (GYG1) Rare No No No Muscle atropy Slowly progressive weakness over decades None Remarks: * Some<unk> s have different forms, e.g. infantile, juvenile, adult (late-onset). * Some<unk> s have different subtypes, e.g.<unk> 1a /<unk> 1b,<unk> 9A1 /<unk> 9A2 /<unk> 9B /<unk> 9C /<unk> 9D. *<unk>  type 0: Although<unk>  synthase deficiency does not result in storage of extra<unk>  in the liver, it is often classified with the<unk> s as type 0 because it is another defect of<unk>  storage and can cause similar problems. *<unk>  type VIII <unk>  8): In the past it was considered a distinct condition, however it is now classified with<unk>  type VI or<unk>  IXa1; it has been described as X-linked recessive inherited. *<unk>  type XI <unk>  11): Fanconi-Bickel syndrome, hepatorenal<unk> osis with renal Fanconi syndrome, no longer considered a<unk> . *<unk>  type XIV <unk>  14): Now classed as Congenital disorder of glycosylation type 1 (CDG1T), affects the phosphoglucomutase enzyme (gene PGM1). * Lafora<unk>  is considered a complex neurodegenerative<unk>  and also a<unk>  metabolism disorder.
Glycogen storage disease
Neutral lipid storage disease
Lysosomal storage disease
Inborn errors of carbohydrate metabolism
Lysinuric protein intolerance
Mucopolysaccharidosis
Gangliosidosis
Lipid storage disorder